.jpeg)
{{ variable.name }}
Cabozantinib is a multi-target tyrosine kinase inhibitor (TKI) that blocks tumor angiogenesis and inhibits tumor cell proliferation and metastasis by selectively inhibiting the activity of MET, VEGFR-1/2/3, AXL, RET, ROS1 and other receptor tyrosine kinases.
Cabozantinib is a multi-target tyrosine kinase inhibitor, suitable for the following conditions:
Renal cell carcinoma (RCC) :
Single Drug treatment for patients with advanced renal cell carcinoma
Combined with nivolumab as first-line treatment for advanced RCC
Hepatocellular carcinoma (HCC) :Treatment of patients with hepatocellular carcinoma who have received sorafenib p>
Differentiated thyroid cancer (DTC) : Treatment of locally advanced or metastatic DTC patients aged 12 years and above who are refractory to radioactive iodine or are not suitable for radioactive iodine therapy, and who have previously received VEGFR targeted therapy Post-Progression
Neuroendocrine tumors (NETs) : Treatment of patients 12 years of age and older with previously treated unresectable locally advanced or metastatic pancreatic (pNET) or extrapancreatic (epNET) well-differentiated Neuroendocrine tumors
Adults and adolescents weighing ≥40kg:60 mg orally daily Once (monotherapy)
In combination with nivolumab:40 mg once daily
Adolescents weighing <40 kg:40 mg once daily
Take the drug Requirements for :Take on an empty stomach (1 hour before a meal or 2 hours after a meal), swallow the whole tablet and do not crush/chew it
Dose adjustment :Gradually reduce the dose to 40 mg or more according to the severity of adverse reactions. 20 mg once a day
Surgical management : Stop the drug 3 weeks before surgery, resume medication at least 2 weeks after the surgery and after the wound has healed
Handling of missed doses :If more than 12 doses are missed Skip the dose every hour
Single drug therapy : Diarrhea , fatigue, hand-foot skin reaction, decreased appetite, hypertension, nausea, vomiting, weight loss
Combined treatment : Diarrhea, fatigue, hepatotoxicity, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain p>
Bleeding risk : Fatal bleeding may occur, patients with recent bleeding history are contraindicated
Perforation/fistula : b>Monitor gastrointestinal symptoms and seek medical attention immediately if abdominal pain occurs
Thrombus event : If myocardial infarction requires immediate discontinuation of medication
Hypertensive crisis : Monitor regularly during treatment Blood pressure
Hepatotoxicity : More common when combined with nivolumab
Wound healing disorder : Medication needs to be suspended before and after elective surgery
Jaw Osteonecrosis :An oral examination is required before treatment
Pregnant women : It may cause fetal damage and should be avoided during medication and within 4 months of stopping the medication. Pregnancy
Lactation : Breastfeeding is prohibited during treatment and within 4 weeks of drug withdrawal
Children : Monitor bone growth for those over 12 years old
Liver damageu 200c:Moderate liver impairment requires dose reduction, severe liver impairment avoid use
Avoid combined use with strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin). A 4-hour interval is required between administration of proton pump inhibitors and proton pump inhibitors.
Renal cell carcinoma : The median progression-free survival is 8.6 months for single agent and 16.6 months for combination with nivolumab
Liver cells Cell carcinoma :Median overall survival 10.2 months (vs placebo 8.0 months)
Thyroid cancer :Median PFS 11.0 months (vs placebo 1.9 months)